Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
The group is keeping faith with the novel target KLK2.
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.
The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.
Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.
